Profusa, Inc. PFSA 深 滬
已收盤 02-06 16:00:00 美东时间
0.0583
+0.004
+6.39%
華盛通- 最 高0.06
- 今 開0.0523
- 成交量 555.60万股
- 最 低 0.0517
- 昨 收 0.0548
- 總市值 503.80万
- 52周最高 2.40
- 市盈率 靜 --
- 換手率 6.43%
- 52周最低 0.0517
- 委 比 -99.60%
- 總股本 8641.43万
- 歷史最高 2.40
- 量 比 0.92
- 振 幅 15.15%
- 歷史最低 0.0517
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Profusa shares are trading lower after the company announced a 1-for-75 reverse stock split.
Profusa shares are trading lower after the company announced a 1-for-75 reverse...
02-05 23:31
Profusa Announces 1-For-75 Reverse Stock Split, Effective Feb. 9
Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry,
02-05 21:03
Profusa Rolls Out Healthcare Research Version Of Lumee Tissue Oxygen Monitoring
Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's
01-16 20:31
Profusa Stock Soars—To 12 Cents—On Debt Restructuring
Profusa stock soars after the company announced the restructuring of its debt and a reduction in potential shareholder dilution.
2025-12-31 05:22
Why OceanFirst Financial Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of OceanFirst Financial Corp. (NASDAQ:OCFC) fell sharply during Tuesday'...
2025-12-31 01:31
Profusa Abstract Accepted For LINC 2026; Presentation To Highlight Tissue Oxygen Monitoring Insights In PAD Pilot Study
Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patientsBERKELEY, Calif, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage
2025-12-11 21:37
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Addex Therapeutics (NASDAQ:ADXN) stock rose 12.1% to $8.18 during Mond...
2025-11-25 05:05
Profusa CEO Says 'Co To Capitalize On The Near-Term European And U.S. Lumee Oxygen Opportunity To Deliver 2026 Potential Revenue Of $500K To $2M And $9M To $13M Potential Revenue In 2027
Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual's biochemistry,
2025-11-20 06:56
STRATA Skin Sciences Rises 25% Pre-Market — Here's Why
STRATA gained on premarket trading after receiving Mexican regulatory approval for its TheraClearX acne treatment system.
2025-10-29 16:43
Why Profusa (PFSA) Stock Soared 36% After Hours?
Profusa shares jumped 36% in after-hours trading after the company completed key manufacturing milestones and outlined plans to start generating revenue from its Lumee systems in early 2026.
2025-10-29 15:30
